11 completed, 6 active not recruiting, 4 unknown, 2 terminated. 25 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Completed 11, Active not recruiting 6, Unknown 4, Terminated 2, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Animal Diseases: new trials by email Literature Review of Animal Diseases trials Research Report on Animal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nitazoxanide for Treatment of Cryptosporidium in Children Nitazoxanide, Placebo - Cryptosporidiosis | Phase 3 | Not yet recruiting | Johns Hopkins Bloomberg School of Public Health | 480 | 2026-12-30 | 2026-09-28 |
| A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults mRNA-1018-H5, Placebo - Influenza | Phase 3 | Active not recruiting | ModernaTX, Inc. | 4050 | 2026-03-23 | 2026-08-11 |
| Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) H5N1 vaccine (Arepanrix, GSK), Placebo - Influenza (Pandemic), Avian Influenza | Phase 3 | Active not recruiting | University Health Network, Toronto | 120 | 2025-11-03 | 2026-10-23 |
| Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP) - Neonate, Maternal Transmission | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 359 | 2025-06-23 | 2026-01-30 |
| Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN half-dose regimen - Mpox (Monkeypox), Vaccination | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 344 | 2025-05-29 | 2026-04-29 |
| Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia LC16m8 - Monkeypox | Phase 3 | Active not recruiting | Universidad Nacional de Colombia | 8686 | 2023-12-16 | 2025-09-04 |
| Tecovirimat in Non-hospitalized Patients With Monkeypox Tecovirimat, Placebo - Monkeypox | Phase 3 | Suspended | Marina Klein | 120 | 2023-08-14 | 2026-03-04 |
| Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease Tecovirimat, Placebo - Monkeypox, Mpox | Phase 3 | Active not recruiting | ANRS, Emerging Infectious Diseases | 480 | 2023-03-03 | 2026-05-26 |
| Study of Tecovirimat for Human Mpox Virus Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label) - MPOX | Phase 3 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 719 | 2022-09-08 | 2026-06-23 |
| Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years VAC∆6 vaccine (10⁷ PFU), VAC∆6 vaccine (10⁶ PFU), Live Smallpox Vaccine - Smallpox, Monkeypox | Phase 2 / Phase 3 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 334 | 2021-10-01 | 2023-05-06 |
| FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues Immunohistochemical staining with anti-FOS - Colorectal Cancer, Monkey Pox | Phase 2 / Phase 3 | Unknown | xiaoliang Huang | 120 | 2020-12-01 | 2023-01-26 |
| A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children EV71 vaccine, Placebo - Enterovirus Infections | Phase 3 | Completed | Enimmune Corporation | 3982 | 2018-06-27 | 2026-09-11 |
| A Safety and Immunogenicity Study of IVACFLU-A/H5N1 IVACFLU-A/H5N1 vaccine, Placebo - Avian Influenza | Phase 2 / Phase 3 | Completed | Institute of Vaccines and Medical Biologicals, Vietnam | 930 | 2017-03-07 | 2019-05-21 |
| JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo JYNNEOS (Liquid Formulation), JYNNEOS (Lyophilized Formulation) - Monkeypox Virus Infection | Phase 3 | Completed | Centers for Disease Control and Prevention | 1600 | 2017-02-23 | 2026-04-23 |
| A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age aH5N1c, Placebo - Avian Influenza | Phase 3 | Completed | Seqirus | 3196 | 2016-07-11 | 2024-12-06 |
| Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine - Influenza, Human | Phase 3 | Completed | Seqirus | 540 | 2014-04-01 | 2016-11-04 |
| Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine - Influenza, Human, Flu, Human | Phase 3 | Completed | Seqirus | 539 | 2014-04-01 | 2016-05-09 |
| Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers MG1109, Placebo - Influenza | Phase 3 | Completed | Green Cross Corporation | 420 | 2013-08-01 | 2015-07-03 |
| Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa adalimumab, placebo - Hidradenitis Suppurativa (HS) | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 307 | 2011-11-01 | 2021-07-07 |
| Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa adalimumab, placebo - Hidradenitis Suppurativa (HS) | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 326 | 2011-11-01 | 2021-07-12 |
Showing 20 of 25. Sign in to see all of them.
Mpox, Monkeypox (9) · Influenza in Birds (8) · Influenza, Human (6) · Acne Vulgaris (3) · Furunculosis (3) · Smallpox (3) · Cryptosporidiosis (2) · Hidradenitis Suppurativa (2) · Psoriasis (2) · AIDS-Related Opportunistic Infections (1) · Colorectal Neoplasms (1) · Cowpox (1) · Enterovirus Infections (1) · Eosinophilia (1) · Foot-and-Mouth Disease (1)
Infections (25) · Virus Diseases (19) · DNA Virus Infections (10) · RNA Virus Infections (10) · Poxviridae Infections (9) · Primate Diseases (9) · Rodent Diseases (9) · Bird Diseases (8) · Orthomyxoviridae Infections (8) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Digestive System Diseases (4) · Acneiform Eruptions (3) · Bacterial Infections (3)
tecovirimat (3) · Adalimumab (2) · nitazoxanide (2) · Albendazole (1) · Oxytetracycline (1) · arepanrix (1) · halofantrine (1) · smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (1) · smallpox vaccine LC16m8 (1)
Seqirus (3) · AbbVie (prior sponsor, Abbott) (2) · Jean-Pierre Van geertruyden (2) · ANRS, Emerging Infectious Diseases (1) · Alachua Government Services, Inc. (1) · Centers for Disease Control and Prevention (1) · Enimmune Corporation (1) · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (1) · Green Cross Corporation (1) · Hospital de Niños R. Gutierrez de Buenos Aires (1) · Institute of Vaccines and Medical Biologicals, Vietnam (1) · Johns Hopkins Bloomberg School of Public Health (1) · Laboratorios Goulart S.A. (1) · Marina Klein (1) · ModernaTX, Inc. (1)
United States (4) · Argentina (3) · Brazil (3) · Democratic Republic of the Congo (3) · Canada (2) · Germany (2) · Vietnam (2) · Australia (1) · China (1) · Colombia (1) · Croatia (1) · Italy (1) · Japan (1) · Mexico (1) · Peru (1)
Alexander Geisberger, MD (1) · Andrea Gerbase (1) · Carlos Machado (1) · Chin-Fen Yang (1) · David Williams, MD (1) · Denise Steiner (1) · Faisal Minhaj, Pharm.D., MPH, DABAT (1) · Hector Freilij, MD (1) · Igor Antoncic, MD, MSc (1) · Irina V Krasil'nikova, PhD (1) · Jaime Altcheh, MD (1)
PMID 27518661, PMID 29380251, PMID 39141589, PMID 30445121, PMID 31812464, PMID 35455245, PMID 36263798, PMID 40245474, PMID 41680199, PMID 41740032, PMID 41819114, PMID 41819117, PMID 42372625, PMID 42521300
U01AI167788 (1)